The Orange Pill Podcast

The Orange Pill Podcast

The Orange Pill Podcast 🎙️ Your go-to source for the latest in the dietary supplement and natural health product industry! Brought to you by KGK Science, a global leader in clinical research and regulatory consulting, this podcast delivers:

✔️ Breaking industry news and trends

✔️ Educational insights and practical takeaways

✔️ Discussions on cutting-edge research

✔️ Landmark cases and notable events shaping the field

Join us as we bridge the gap between science, regulation, and everyday impact!

We all try to eat better, loading up on antioxidant-rich berries, turmeric, and green veggies, but here’s the surprising truth: many of those “super-nutrients” never make it past your digestive system. In this episode of the Orange Pill Podcast, hosts Graham Morgan and Dana Mahoney explore how nanotechnology is rewriting the rules of nutrition. From nanoencapsulation that protects fragile compounds like curcumin and quercetin, to upcycling food waste into potent...
Fermented foods like cheese, wine, and cured meats are celebrated for their complex flavors, but they may harbor hidden risks. In this episode of The Orange Pill Podcast, we explore the world of biogenic amines (BAs), naturally occurring compounds that can pose health hazards despite their delicious origins. From the “cheese effect” of tyramine to toxic synergy among multiple amines, we discuss why regulating histamine alone isn’t enough. Learn why...
In Episode 63, we continue to unpack the regulatory evolution of cannabis and cannabidiol (CBD) in Canada, (continuation to Episode 44) and what’s next for the industry. From the Cannabis Act to proposed pathways that could finally allow CBD Natural Health Products (NHPs) to be sold without prescriptions, this episode dives deep into how Health Canada’s changing stance could reshape accessibility, innovation, and economic opportunity....
For most Americans, a government shutdown means furloughs, temporary disruptions that end when funding returns. But October 2025 marks a turning point. The Trump administration’s move to issue Reductions in Force (RIFs) across key agencies like HHS, FDA, and the CDC has transformed a short-term budget standoff into a permanent restructuring of the federal workforce. In this episode, we break down: The difference between a furlough and a RIF, and...
After nearly three years of uncertainty, the FDA has officially reversed its stance on Nicotinamide Mononucleotide (NMN), the popular anti-aging compound once banned from supplement shelves. In this episode, we unpack the twists and turns that led to the agency’s dramatic U-turn, the key legal reinterpretation that changed everything, and how relentless industry advocacy forced the FDA’s hand. From Citizen Petitions to regulatory chaos, discover what really happened behind the...